Compare MGM Resorts International (MGM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs ResMed Inc. — how do they compare? MGM Resorts International trades at $46.57 (market cap $11.86B), while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 2.4× MGM Resorts International's market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| MGM | RMD | |
|---|---|---|
Market Cap | $11.86B | $28.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $293.73 |
52-Week Low | $30.72 | $182.82 |
Enterprise Value | $40.90B | $27.99B |
Dividend Yield | 0.03% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM trades at $45.67, down 1.0% today, with a neutral technical stance and mixed earnings history. The company reported $17.54B revenue in 2025 but net income fell to $206M, with profit margins narrowing. Recent news highlights acquisition interest from Barry Diller at $48.30 per share, creating investor uncertainty. Cash flow trends show improving operational strength, though net cash flow remains negative.
Outlook is balanced: potential upside exists from the acquisition offer and steady revenue, but risks include declining profitability and high debt. Analysts are split evenly between Buy and Hold, with a $48.93 consensus target suggesting modest upside. Investors should weigh takeover prospects against fundamental pressures.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
